Fitlife Brands, Inc.
FTLF Nasdaq Medicinal Chemicals & Botanical Products Financials FY2016βFY2025
Last close Β· Oct 23, 2026
$8.35
1.5%What Fitlife Brands, Inc. does
No business description yet.
- Legal name
- FITLIFE BRANDS, INC.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 31, 2026
- Accession Β· CIK
- 0001437749-26-010680
0001374328
Revenue and margins
Fitlife Brands, Inc. had $15.9M of revenue in fiscal 2025, down 75.3% on the year before.
Net income and earnings per share
From fiscal 2016 to 2025, diluted EPS grew 19.6% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $7.4M in fiscal 2025, 46.4% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Fitlife Brands, Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 0.3%.
Balance sheet
Cash, debt and the ratios that show how comfortably Fitlife Brands, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $9.9M | $13.3M | $1.1M | $4.5M | $1.6M |
| Debt incl. finance leases | β | $0.0M | $20.1M | $13.1M | β |
| Net debt / EBITDA | β | β2.3x | 2.5x | 0.6x | β |
| Debt / equity | β | 0.0x | 0.7x | 0.4x | β |
| Interest coverage | β | β | 7.4x | 9.6x | 13.6x |
| Current ratio | 4.4x | 5.4x | 1.4x | 1.6x | 1.5x |
| Quick ratio | 2.8x | 3.3x | 0.5x | 0.6x | 0.5x |
| Total assets | $21.5M | $25.7M | $55.3M | $58.5M | $106M |
| Total liabilities | $4.2M | $4.3M | $28.3M | $22.4M | $62.7M |
| Shareholders' equity | $17.3M | $21.4M | $27.0M | $36.1M | $43.6M |
| Net debt (β = net cash) | β | β$13.3M | $19.0M | $8.6M | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 5 / 9 | 8 / 9 | 7 / 8 | 5 / 8 | 4 / 8 | 4 / 8 | 2 / 9 | 8 / 9 | 3 / 8 |
| Accruals ratio | 2.1% | β1.4% | 3.8% | 5.7% | 27.4% | 4.9% | 1.3% | 2.7% | β1.1% | β6.6% |
| Altman Z'' | β | β | β | β8.04 | 3.75 | 8.49 | 10.42 | 2.23 | 4.28 | 1.99 |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $25.3M | $17.8M | $17.1M | $19.5M | $21.7M | $27.9M | $28.8M | $52.7M | $64.5M | $15.9M |
| Net interest income | β | β | β | β | β$0.0M | $0.0M | $0.1M | β | β | β |
| Gross profit | $10.1M | $5.1M | $6.7M | $8.0M | $9.5M | $12.5M | $12.0M | $21.4M | $28.1M | $6.9M |
| Operating income | $0.5M | β$9.0M | $0.7M | $2.5M | $4.3M | $6.2M | $5.7M | $7.6M | $13.1M | $3.0M |
| Interest expense | $0.1M | $0.1M | $0.1M | $0.0M | $0.0M | β | $0.0M | $1.0M | $1.4M | $0.2M |
| Pretax income | $0.4M | β$9.1M | $0.5M | $2.6M | $4.4M | $6.7M | $5.8M | $7.0M | $11.9M | $2.7M |
| Income tax | $0.0M | $0.7M | $0.0M | $0.0M | β$4.4M | $1.3M | $1.4M | $1.7M | $2.9M | $0.7M |
| Net income | $0.4M | $0.5M | $0.5M | $2.6M | $8.8M | $5.4M | $4.4M | $5.3M | $9.0M | $2.0M |
| Net income to common | β | β$9.8M | $0.4M | $2.5M | $8.8M | β | β | β | β | β |
| Diluted EPS | $0.04 | β$0.93 | $0.37 | $2.33 | $7.76 | $1.13 | $0.89 | $0.54 | $0.91 | $0.20 |
| Diluted shares | 0.01B | 0.01B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.01B | 0.01B | 0.01B |
| Cash flow | ||||||||||
| Cash from operations | $0.0M | $0.7M | $0.3M | $2.3M | $5.7M | $4.5M | $4.1M | $4.2M | $9.6M | $7.4M |
| Capital expenditure | $0.0M | $0.2M | $0.0M | β | β | β | $0.0M | $0.1M | $0.0M | $0.0M |
| Free cash flow | $0.0M | $0.5M | $0.3M | β | β | β | $4.1M | $4.1M | $9.6M | $7.4M |
| Depreciation and amortization | $0.1M | $0.1M | $0.1M | $0.1M | $0.0M | $0.1M | $0.1M | $0.1M | $0.1M | $0.4M |
| Stock-based compensation | β | β | $0.1M | $0.1M | $0.0M | $0.1M | $0.1M | β | β | β |
| Share buybacks | $0.2M | $0.0M | $0.0M | $1.5M | $0.2M | $0.4M | $0.8M | $0.0M | β | β |
| Dividends paid | β | β | $0.0M | $0.1M | $0.0M | β | β | β | β | β |
| Dividends and buybacks | $0.2M | $0.0M | $0.0M | $1.6M | $0.2M | $0.4M | $0.8M | $0.0M | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $1.3M | $1.3M | $0.3M | $0.3M | $6.3M | $9.9M | $13.3M | $1.1M | $4.5M | $1.6M |
| Total debt | $3.4M | $2.8M | $0.0M | β | β | β | $0.0M | $20.1M | $13.1M | β |
| Loans, net | β | $0.0M | β | β | β | β | β | β | β | β |
| Current assets | $7.9M | $6.3M | $5.9M | $5.4M | $11.8M | $17.7M | $23.2M | $14.7M | $18.1M | $33.1M |
| Current liabilities | $4.5M | $6.0M | $4.0M | $2.8M | $4.1M | $4.1M | $4.3M | $10.3M | $11.3M | $21.6M |
| Inventory | $3.8M | $2.9M | $3.5M | $3.4M | $3.5M | $6.5M | $9.1M | $9.1M | $11.1M | $21.3M |
| Property and equipment, net | $0.2M | $0.3M | $0.2M | $0.1M | $0.1M | $0.1M | $0.0M | $0.1M | $0.1M | $0.1M |
| Goodwill | $6.5M | $0.2M | $0.2M | $0.2M | $0.2M | $0.4M | $0.4M | $13.3M | $13.0M | $19.4M |
| Intangible assets | $6.5M | $0.2M | β | β | $0.0M | $0.2M | $0.2M | $26.3M | $26.2M | $51.4M |
| Total assets | $15.4M | $6.9M | $6.3M | $6.0M | $16.6M | $21.5M | $25.7M | $55.3M | $58.5M | $106M |
| Total liabilities | $4.8M | $6.0M | $4.0M | $3.0M | $4.8M | $4.2M | $4.3M | $28.3M | $22.4M | $62.7M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $0.9M | $0.9M | $2.1M | $3.1M | $11.9M | $17.3M | $21.4M | $27.0M | $36.1M | $43.6M |
| Margins | ||||||||||
| Gross margin | 39.8% | 28.6% | 39.5% | 40.9% | 43.9% | 44.8% | 41.8% | 40.7% | 43.6% | 43.1% |
| Operating margin | 1.9% | β50.3% | 3.8% | 12.8% | 20.0% | 22.3% | 19.8% | 14.3% | 20.3% | 18.6% |
| EBITDA margin | 2.1% | β50.0% | 4.2% | 13.1% | 20.2% | 22.5% | 20.0% | 14.5% | 20.5% | 21.2% |
| Net margin | 1.5% | 2.9% | 3.0% | 13.4% | 40.6% | 19.4% | 15.4% | 10.0% | 13.9% | 12.7% |
| FCF margin | 0.1% | 2.7% | 1.5% | β | β | β | 14.3% | 7.8% | 14.9% | 46.4% |
| Net interest share of revenue | β | β | β | β | β0.0% | 0.1% | 0.4% | β | β | β |
| Returns | ||||||||||
| Return on capital | 15.5% | β291.0% | 34.1% | β | β | β | 53.5% | 12.4% | 22.2% | β |
| Return on capital employed | 4.3% | β981.6% | 28.2% | 76.0% | 34.8% | 35.7% | 26.6% | 16.8% | 27.8% | 3.5% |
| Return on equity | 40.4% | 55.8% | 33.5% | 100.3% | 118.1% | 37.0% | 22.9% | 21.9% | 28.4% | 5.1% |
| Return on assets | 2.4% | 4.6% | 7.7% | 42.3% | 77.9% | 28.4% | 18.8% | 13.1% | 15.8% | 2.4% |
| Return on tangible equity | β | β2,112.8% | 21.2% | 89.5% | 75.8% | 32.2% | 21.2% | β | β | β |
| Growth | ||||||||||
| Revenue growth | β | β29.7% | β4.1% | 14.2% | 11.5% | 28.4% | 3.2% | 83.0% | 22.3% | β75.3% |
| Net income growth | β | 38.3% | 0.0% | 412.8% | 238.1% | β38.7% | β18.1% | 19.6% | 69.6% | β77.5% |
| EPS growth | β | β2,425.0% | β | 529.7% | 233.0% | β85.4% | β21.2% | β39.3% | 68.5% | β78.0% |
| FCF growth | β | 1,839.5% | β46.4% | β | β | β | β | β0.4% | 133.3% | β22.9% |
| Share count change | β | 1.7% | β89.6% | β0.2% | 4.1% | 322.2% | β99.9% | 196,100.0% | 0.9% | 0.3% |
| Financial health | ||||||||||
| Net debt / EBITDA | 4.0x | β | β0.4x | β | β | β | β2.3x | 2.5x | 0.6x | β |
| Debt / equity | 3.8x | 3.0x | 0.0x | β | β | β | 0.0x | 0.7x | 0.4x | β |
| Interest coverage | 4.3x | β79.9x | 4.9x | 53.0x | 289.7x | β | β | 7.4x | 9.6x | 13.6x |
| Current ratio | 1.8x | 1.1x | 1.5x | 2.0x | 2.8x | 4.4x | 5.4x | 1.4x | 1.6x | 1.5x |
| Quick ratio | 0.9x | 0.6x | 0.6x | 0.7x | 2.0x | 2.8x | 3.3x | 0.5x | 0.6x | 0.5x |
| Capital allocation | ||||||||||
| Capex / revenue | 0.1% | 1.0% | 0.0% | β | β | β | 0.0% | 0.2% | 0.0% | 0.3% |
| Stock comp / revenue | β | β | 0.8% | 0.6% | 0.1% | 0.4% | 0.3% | β | β | β |
| Payouts / FCF | 632.7% | 0.0% | 0.0% | β | β | β | 18.9% | 0.0% | β | β |
| Quality scores | ||||||||||
| Piotroski F-score | β | 5.0 | 8.0 | 7.0 | 5.0 | 4.0 | 4.0 | 2.0 | 8.0 | 3.0 |
| Altman Z'' | β | β | β | β8.0 | 3.7 | 8.5 | 10.4 | 2.2 | 4.3 | 2.0 |
| Accruals ratio | 2.1% | β1.4% | 3.8% | 5.7% | 27.4% | 4.9% | 1.3% | 2.7% | β1.1% | β6.6% |
Source: SEC EDGAR XBRL filings (CIK 0001374328). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.